Junshi Bio Chairman Concludes RMB100.64 Million Share Purchase; Controlling Group Stake Rises to 18.24%

Bulletin Express03-31

Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that Chairman and co-controlling shareholder Xiong Jun has completed his previously announced share-purchase plan, acquiring 3.26 million A and H shares between 10 November 2025 and 31 March 2026. The purchases, executed via Shanghai and Hong Kong bourses through centralised bidding and block trades, totalled RMB100.64 million—exceeding the minimum RMB100 million commitment outlined on 12 April 2025.\n\nFollowing the transactions, the combined holding of Xiong Jun, fellow controlling shareholder Xiong Fengxiang, and their concert-party investors (including Shanghai Baoying Asset Management, Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management, Zhou Yuqing, Liu Xiaoling and Wang Lifang) increased from 17.92% to 18.24% of Junshi Bio’s 1.03 billion outstanding shares. The 0.32-percentage-point uplift crossed the statutory 1% incremental disclosure threshold but does not trigger a mandatory general offer.\n\nXiong Jun’s direct stake rose from 8.56% to 8.87% after purchasing 2.36 million A shares and 0.89 million H shares. All acquisitions were funded with personal resources. No changes occurred in Junshi Bio’s controlling shareholder structure, and the company stated that its public float remains compliant with listing requirements.\n\nJunshi Bio reiterated that the share-purchase plan has now been fully executed, with no further increases mandated under the disclosed programme.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127493446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127493446","market":"hk","top_or_hot":-1,"title":"Junshi Bio Chairman Concludes RMB100.64 Million Share Purchase; Controlling Group Stake Rises to 18.24%","media":"Bulletin Express","content":"<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that Chairman and co-controlling shareholder Xiong Jun has completed his previously announced share-purchase plan, acquiring 3.26 million A and H shares between 10 November 2025 and 31 March 2026. The purchases, executed via Shanghai and Hong Kong bourses through centralised bidding and block trades, totalled RMB100.64 million—exceeding the minimum RMB100 million commitment outlined on 12 April 2025.\\n\\nFollowing the transactions, the combined holding of Xiong Jun, fellow controlling shareholder Xiong Fengxiang, and their concert-party investors (including Shanghai Baoying Asset Management, Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management, Zhou Yuqing, Liu Xiaoling and Wang Lifang) increased from 17.92% to 18.24% of Junshi Bio’s 1.03 billion outstanding shares. The 0.32-percentage-point uplift crossed the statutory 1% incremental disclosure threshold but does not trigger a mandatory general offer.\\n\\nXiong Jun’s direct stake rose from 8.56% to 8.87% after purchasing 2.36 million A shares and 0.89 million H shares. All acquisitions were funded with personal resources. No changes occurred in Junshi Bio’s controlling shareholder structure, and the company stated that its public float remains compliant with listing requirements.\\n\\nJunshi Bio reiterated that the share-purchase plan has now been fully executed, with no further increases mandated under the disclosed programme.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Bio Chairman Concludes RMB100.64 Million Share Purchase; Controlling Group Stake Rises to 18.24%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Bio Chairman Concludes RMB100.64 Million Share Purchase; Controlling Group Stake Rises to 18.24%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-31 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that Chairman and co-controlling shareholder Xiong Jun has completed his previously announced share-purchase plan, acquiring 3.26 million A and H shares between 10 November 2025 and 31 March 2026. The purchases, executed via Shanghai and Hong Kong bourses through centralised bidding and block trades, totalled RMB100.64 million—exceeding the minimum RMB100 million commitment outlined on 12 April 2025.\\n\\nFollowing the transactions, the combined holding of Xiong Jun, fellow controlling shareholder Xiong Fengxiang, and their concert-party investors (including Shanghai Baoying Asset Management, Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management, Zhou Yuqing, Liu Xiaoling and Wang Lifang) increased from 17.92% to 18.24% of Junshi Bio’s 1.03 billion outstanding shares. The 0.32-percentage-point uplift crossed the statutory 1% incremental disclosure threshold but does not trigger a mandatory general offer.\\n\\nXiong Jun’s direct stake rose from 8.56% to 8.87% after purchasing 2.36 million A shares and 0.89 million H shares. All acquisitions were funded with personal resources. No changes occurred in Junshi Bio’s controlling shareholder structure, and the company stated that its public float remains compliant with listing requirements.\\n\\nJunshi Bio reiterated that the share-purchase plan has now been fully executed, with no further increases mandated under the disclosed programme.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1127493446","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127493446","pubTimestamp":1774962260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that Chairman and co-controlling shareholder Xiong Jun has completed his previously announced share-purchase plan, acquiring 3.26 million...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"君实生物董事长完成人民币10064万元股份购买；控股集团持股升至18.24%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shanghai Junshi Biosciences Co., Ltd. (Junshi Bio) confirmed that Chairman and co-controlling shareholder Xiong Jun has completed his previously announced share-purchase plan, acquiring 3.26 million A and H shares between 10 November 2025 and 31 March 2026. The purchases, executed via Shanghai and Hong Kong bourses through centralised bidding and block trades, totalled RMB100.64 million—exceeding the minimum RMB100 million commitment outlined on 12 April 2025.\\n\\nFollowing the transactions, the combined holding of Xiong Jun, fellow controlling shareholder Xiong Fengxiang, and their concert-party investors (including Shanghai Baoying Asset Management, Meng Xiaojun, Gao Shufang, Zhuhai Huapu Investment Management, Zhou Yuqing, Liu Xiaoling and Wang Lifang) increased from 17.92% to 18.24% of Junshi Bio’s 1.03 billion outstanding shares. The 0.32-percentage-point uplift crossed the statutory 1% incremental disclosure threshold but does not trigger a mandatory general offer.\\n\\nXiong Jun’s direct stake rose from 8.56% to 8.87% after purchasing 2.36 million A shares and 0.89 million H shares. All acquisitions were funded with personal resources. No changes occurred in Junshi Bio’s controlling shareholder structure, and the company stated that its public float remains compliant with listing requirements.\\n\\nJunshi Bio reiterated that the share-purchase plan has now been fully executed, with no further increases mandated under the disclosed programme.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127493446","isCrawlerRequest":true}